flâneur

姿雅羅

1 followers · 268 views

on the atlas · 26

highlights · 65

Oral cavity: right tongue ulcerative mass, 7*4cm, with induration and very tenderness, DOI might be >10mm Oropharynx: normal finding Nasopharynx: sensitive Neck: LAP(-)
作業of口腔癌
based on cytogenetic and molecular features
Acute myeloid leukemia in children and adolescents - UpToDate
controversy about certain high-risk molecular features
Acute myeloid leukemia in children and adolescents - UpToDate
controversy about certain high-risk molecular features
Acute myeloid leukemia in children and adolescents - UpToDate
副腫瘤皮膚病變(paraneoplastic dermatoses)
副腫瘤症候群的皮膚表現
Transplantation must also consider the age of the child
Hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in children and adolescents - UpToDate
measurable residual disease (MRD
Acute myeloid leukemia in children and adolescents - UpToDate
controversy about certain high-risk molecular features
Acute myeloid leukemia in children and adolescents - UpToDate
treatment delay versus harm from COVID-19
Acute myeloid leukemia in children and adolescents - UpToDate
whether a mother’s age affects the probability of having a baby with a low birthweight
Adjusted Odds Ratio: Definition + Examples - Statology
adjusted to account for other predictor variables in a model
Adjusted Odds Ratio: Definition + Examples - Statology
= (7.9 × 61.6%) + (450.4 × 38.4%)
Age-standardized Rates
the standard population weight
Age-standardized Rates
first calculate the age-specific (mortality) rates for each age group
Age-standardized Rates
Calculation of the Age-standardized Rate
Age-standardized Rates
account for the differences in the age structure of the populations being compared
Age-standardized Rates
Age-standardized Rates
Age-standardized Rates
case fatality rates (CFRs)
The age-standardized incidence, mortality, and case fatality rates of COVID-19 in 79 countries: a cross-sectional comparison and their correlations with associated factors
age-standardized rates are more suitable for comparisons
The age-standardized incidence, mortality, and case fatality rates of COVID-19 in 79 countries: a cross-sectional comparison and their correlations with associated factors
It is generally accepted to offer patients with poor-risk cytogenetics allogeneic HCT as consolidation therapy, although the data supporting this approach are limited.
Acute myeloid leukemia in children and adolescents - UpToDate
The role of allogeneic HCT in children and adolescents with AML continues to be an area of active investigation and there is no general consensus among experts.
Acute myeloid leukemia in children and adolescents - UpToDate
moAbs can either act as an agonist (e.g. death receptor) or antagonist (e.g. growth receptor) to a given receptor on the tumor thereby facilitating cytotoxicity or growth arrest
Immunotherapy in pediatric malignancies: current status and future perspectives
monoclonal antibodies (moAbs) show anti-tumor responses in a variety of childhood cancers
Immunotherapy in pediatric malignancies: current status and future perspectives
CAR-T細胞療法一樣也有它的副作用，最重要的副作用是細胞介質釋放症候群（Cytokine Release Syndrome，CRS）
癌症治療的海豹特種部隊淺談CAR-T細胞治療法::台灣癌症基金會
CAR分子就是一部分T細胞受體與一部分癌細胞特異抗原單株抗體結合在一起的混合接受器
癌症治療的海豹特種部隊淺談CAR-T細胞治療法::台灣癌症基金會
Chimeric Antigen Receptor
癌症治療的海豹特種部隊淺談CAR-T細胞治療法::台灣癌症基金會
CAR-T細胞（chimeric antigen receptor-T cell）
癌症治療的海豹特種部隊淺談CAR-T細胞治療法::台灣癌症基金會
E6和E7兩個早期基因被認為和導致子宮頸癌最有關係，他們抑制了p53以及Rb兩個腫瘤抑制基因，分別與腫瘤抑制基因p53 及Rb腫瘤抑制蛋白結合，使其抑制細胞增殖的功喪失
婦產科方嘉宏醫師 - 人類乳突病毒(HPV)
EBNA-1 protein is expressed in all EBV infected cells, and IgG against this protein is a late marker of EBV infection
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
Different detection methods are available commercially. Some commercial primers and probes target include LMP-2 gene, BHRF-1 (a transmembrane protein), BKRF1 (EBNA-1 gene), BNRF1 (a major tegument protein), BXLF1 (thymidine kinase), BZLF1 (ZEBRA), or BALF5 (viral DNA polymerase)
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
qRT-PCR as a sensitive and reliable method and a complementary tool to other serologic markers, in particular, for diagnosis of EBV acute infection and EBV silent reactivation
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
Infected naive B lymphocytes become activated lymphoblasts and migrate to the lymph node follicle to initiate a reaction in the germinal center of the follicle using the “latency III” program, where all latent growth proteins are expressed and adversely regulate the EBV growth.
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
a variant with 30-bp deletion was frequently detected in NPC patients, and this variant showed higher transforming activity than the typical LMP-1
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
has the ability to block apoptosis by upregulating different anti-apoptotic proteins such as A20 and Bcl-2 and inhibiting the p53-mediated apoptosis
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
LMP-1 is the only protein with oncogenic properties
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
the EBV can induce errors during replication and creates more genetic variability between individuals
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
the nature of the EBV life cycle within the lymphocytes
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
differ in their transformation abilities
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
differ in their transformation abilities
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
Type 1 and 2 can further be subtyped into different EBV strains
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
two different EBV genotypes: Type 1 and Type 2, also known as Type A and B, respectively
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
synthesized in the lytic cycle of the EBV replication (105
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
proteins and glycoproteins
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
(EA) antibodies to the class R or D increase in the acute phase of infection and decline after convalescence.
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
Epstein Barr nuclear antigens (EBNA) antibodies are detectable late in the phase of infection and also remain positive
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
VCA-IgG increases at the same time of VCA-IgM, but it remains positive for life indicating past infection.
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
Viral capsid antigens (VCA)-IgM is detected in the active phase
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
the genes used in the test are genes that codes for the viral capsid antigens (VCAs), the early antigens (EAs), as well as the genes that code for Epstein–Barr nuclear antigens (EBNAs)
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
capsid of 162 capsomers
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology
toroid-shaped protein core wrapped with the viral DNA
Frontiers | Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update | Oncology